Table 1 Differences and comparison between mucinous and non-mucinous patients with colorectal cancer in 14 clinical trials
From: Mucinous colorectal adenocarcinoma: clinical pathology and treatment options
Clinical trial | Type of hemotherapy | Stage | Chemotherapy regimen | Patients (n, MC/NMC) | Median OS (months) | OS rate (%) | HR | ||
|---|---|---|---|---|---|---|---|---|---|
MC | NMC | MC | NMC | ||||||
Tumor location: colorectal | |||||||||
Negri 2005 [63] | Palliative | IV | 5-FU based first-line chemotherapy | 135 (45/90) | 11.8 | 17.9 | – | – | 1.50 |
Catalano 2009 [8] | Palliative | IV | 5-FU with OXA and/or CPT-11 based first-line combination chemotherapy | 255 (49/206) | 14.0 | 23.4 | 53.1% (1-year) | 77.4% (1-year) | 1.59 |
Mekenkamp Study 1 2012 [64] | Palliative | IV | First-line sequential or combination treatment with CAP, CPT-11 and OXA. | 485 (50/435) | 13.2 | 19.2 | – | – | 1.80 |
Mekenkamp Study 2 2012 [64] | Palliative | IV | CAP, OXA and BEV with or without CET | 525 (49/476) | 13.1 | 21.5 | – | – | 1.76 |
Park 2015 [65] | Adjuvant | I–III | 5-FU based chemotherapy | 6475 (274/6201) | – | – | 81.4% (5-year) | 87.4% (5-year) | 1.58 |
Tumor location: colon | |||||||||
Maisano 2012 [60] | Palliative | IV | FOLFOX-4 regimen [OXA, LV, 5-FU] | 63 (21/42) | 8.0 | 18.0 | – | – | 1.99 |
Catalano 2012 [23] | Adjuvant | II–III | Fluoropyrimidine-based or OXA-based chemotherapy | 1025 | – | – | 78.6% (5-year) | 72.3% (5-year) | 0.89 |
Kim 2013 [14] | Adjuvant chemotherapy | III | FOLFOX chemotherapy [LV, 5-FU, OXA] | 394 | – | – | 56.9% (3-year DFS) | 79.2% (3-year DFS) | 1.82 |
Tumor location: rectal | |||||||||
Sengul 2006 [66] | PCRT | III–IV | 45–60 Gy and an infusion of 5-FU | 46 (11/35) | – | – | – | – | – |
Grillo-Ruggieri 2007 [98] | PCRT | II–IV | 50.4 Gy and 5-FU-based chemotherapy | 136 (25/111) | – | – | 89.0% (5-year) | 83.9% (5-year) | 0.35 |
Shin 2011 [99] | PCRT | III–IV | 45–50.4 Gy and 5-FU- or CAP-based chemotherapy | 368 (23/345) | – | – | 64.8% (5-year) | 79.8% (5-year) | 2.36 |
Simha 2014 [67] | PCRT | I–IV | 45 Gy and 5-FU and LV | 162 (34,128) | – | – | – | – | – |
Hugen 2015 [69] | PCRT | II–III | 45–50.4 Gy and CAP with or without OXA/BEV or 5-FU | 540 (58/482) | – | – | 53.1% (5-year) | 54.1% (5-year) | – |
Hugen 2013 [9] | Adjuvant | I–IV | 5-FU or CAP with or without OXA | 9045 (744/8301) | – | – | 41.0% (5-year) | 51.2% (5-year) | 1.22 |